Loading in 2 Seconds...
Loading in 2 Seconds...
The Multinational Pharmaceutical Industry Drug Development in its Political Economic Context. World Federation of Public Health Associations Conference Istanbul, Turkey, April 28, 2009. J. Warren Salmon, Ph.D., Visiting Professor
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
The Multinational Pharmaceutical Industry Drug Development in its Political Economic Context
J. Warren Salmon, Ph.D., Visiting Professor
University of Sharjah College of Pharmacy;Professor of Health Policy & Administration
University of Illinois at Chicago
School of Public Health
-- R&D costs (25%)
-- Promotion (25%)
Ingredient costs (10%-15%)
USA, Europe, Japan firms differ historically
CEO Salaries related to performance?
Global Pharmaceutical IndustryPerhaps encountering its most profound period of change since the turn of last century when corporatized. Firms faced difficulties before the world economic collapse.Western multinational PHRMA firms confined to only seven Northern hemisphere nations: U.S., Great Britain, Switzerland, Japan, France, Germany, and Sweden
at a flat rate in 2008
2008 United States drug expenditures of $286.5 billion was slowest growth since 1961. Total volume of scripts (4 billion) climbed only 2.8% (a declining rate). Further decline in 2009 with uninsurance and underinsurance
$17 billion for U.S. generics (PBM push with MC Part D) New introductory medicines only $441 million
Pharma firms looking elsewhere for emerging markets growth
Global Drug MarketFigure of $650 billion includes ethical branded drugs and biologicals (almost 80%), generic drug entities (6-9%), OTCs--NOT including natural medicines and folk remedies, which are majorly used across Asia, Africa, and Latin AmericaU.S. consumption due to high utilization of costly branded entities unregulated as to price, unlike almost every other nation of the world where governments set the prices of drugs
Not pure science
Not to serve public health needs in a country of origin
nor worldwide, for sure
WTO and Bilateral trade agreements (Bush administration)
Will Obama administration change much???
Projected $400 billion over ten years
How much for Pharma firms?
PBMs favored generics
WTO and unilateral trade agreements
(Bush administration action against Thailand over compulsory licensing of Abbott Kaletra)
(Doha holdup with ongoing WTO negotiations)
Weakening public image
Drug access confrontations across the globe
R&D costs, pipeline droughts
High pricing and profit margins???
Drug safety and pharmacovigilance costs
Professor Jack Salmon
University of Sharjah COP and
University of Illinois at Chicago SPH